Yulia Slavina

Solid Biosciences to present seven posters on Duchenne and platform advances at ESGCT2026

Solid Biosciences to present seven posters on Duchenne and platform advances at ESGCT2026
Solid Biosciences at ESGCT2026

Solid Biosciences will deliver seven presentations at ESGCT2026, covering updates on its Duchenne program and platform technologies including POLARIS-101, its next-generation engineered myotropic capsid.

The company is inviting attendees to review their press release and visit their posters to learn more about developments in Duchenne therapies and platform innovation.

Solid Biosciences previously launched POLARIS-101, a next-generation muscle-tropic capsid aimed at advancing gene therapy for neuromuscular and cardiac conditions. The company also shared new research on POLARIS-101 and its INSPIRE DUCHENNE study at a major neuromuscular research event, according to an earlier update detailing data releases. These activities reflect Solid's ongoing focus on innovation in Duchenne therapies and gene delivery platforms.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.